BioCentury | Feb 27, 2020

MPM, Dana-Farber forge philanthropic arrangement around new oncology funds

With the launch of two new funds, MPM Capital and Dana-Farber Cancer Institute each gain access to more of something they felt they were missing. As MPM invests its new $100 million Oncology Innovations Fund,...
BioCentury | Feb 12, 2020

AurorA debuts to back early-stage European biotechs

A new Europe-focused investment vehicle has launched with €10 million in backing from two Italian biopharmas. AurorA Science will be managed by AurorA-TT, a tech transfer company founded in 2017 and led by co-founder, Chairman...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Hydrogel-delivered, thrombin-derived peptide to treat and prevent Staphylococcus and Pseudomonas infections

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus ; Pseudomonas  A polymer-based hydrogel containing the thrombin-derived peptide TCP-25 could treat and prevent S. aureus and P. aeruginosa infections. A hydrogel formulation of 0.1% (0.3nM) TCP-25, which was...
BioCentury | Dec 10, 2019

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

Two and a half years after Perceptive Advisors’ Chris Garabedian launched Xontogeny to foster biotech start-ups’ growth, the firm has created a $210 million fund that will invest in companies the accelerator is nurturing through...
BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Innovations | Oct 8, 2019
Distillery Therapeutics

Inhibiting caspase-mediated pyroptosis for graft-versus-host disease

DISEASE CATEGORY: Transplant INDICATION: Graft-versus-host disease (GvHD) Inhibiting CASP4 or CASP5, the human homologs of murine pyroptosis activator CASP11, or the downstream mediators GSDMD and IL-1α could prevent GvHD in leukemia patients undergoing allogeneic hematopoietic...
BC Extra | Sep 16, 2019
Financial News

Sept. 16 Financial Quick Takes: Karyopharm, Mission Bay, Autolus, BenevolentAI, Edigene

Karyopharm in $150M royalty deal  Karyopharm Therapeutics Inc. (NASDAQ:KPTI) entered into a royalty deal with HealthCare Royalty Partners under which it could receive up to $150 million tied to multiple myeloma drug Xpovio selinexor. Karyopharm...
BioCentury | Sep 9, 2019

4Bio hopes to mix and match next-gen therapies with $150M fund

4Bio Capital is aiming to invest solely in new modalities and treatment paradigms with its new venture fund, including in start-ups that combine more than one novel approach. The firm has raised $50 million in...
BC Extra | Sep 5, 2019
Financial News

Quan doubles down with new $250M fund

With the close of a second fund bringing its managed capital to around $400 million, Quan Capital plans to stick to its strategy of investing in innovative therapeutics, according to Managing Director Marietta Wu. Wu...
BC Extra | Sep 4, 2019
Financial News

Medtech VC Vensana launches with $225M fund, completing Versant’s path to pure biotech

With an inaugural $225 million fund earmarked for late-stage medtech ranging from digital health to surgical devices, Versant Ventures spinout Vensana Capital aims to exploit what it sees as one of the few healthcare sectors...
Items per page:
1 - 10 of 653